Market Overview
The global Interferon Gamma (IFN-γ) ELISA Kit market was valued at USD 13.4 million in 2024 and is projected to reach USD 21.9 million by 2031, exhibiting a compound annual growth rate (CAGR) of 7.5% during the forecast period.
Interferon Gamma (IFN-γ) ELISA Kits are critical diagnostic tools designed to detect and quantify IFNγ protein levels in biological samples. IFN-γ, a cytokine secreted primarily by T cells and natural killer (NK) cells, plays a pivotal role in modulating immune responses, including macrophage activation and pathogen defense. These kits utilize enzyme-linked immunosorbent assay (ELISA) technology, leveraging highly specific antibodies to ensure accurate measurement of IFN-γ concentrations, enabling researchers to assess immune function and disease progression.
USD 21.9 million by 2031 USD 13.4 million in 2024
(CAGR) of 7.5% CAGR
By Type
By Type
Human Segment Dominates the Market Due to Extensive Use in Clinical and Immunological
Research
The Interferon Gamma (IFN-γ) ELISA Kit market is segmented based on type into species-specific variants, reflecting the demand for targeted assays in various research and diagnostic applications:
Human
Mouse
Subtypes: Standard and high-sensitivity variants
Rat
Bovine
Subtypes: For veterinary diagnostics and others
By Application
The market is segmented based on application into key end-use areas, highlighting the diverse utilization of these kits across healthcare and scientific domains: Hospital Research Institute Others
Our Key Players
Elabscience Biotechnology Inc. (China)
Thermo Fisher Scientific Inc. (U.S.)
Abcam plc (U.K.)
Shanghai Korain Biotech Co., Ltd. (China)
Wuhan Fine Biotech Co., Ltd. (China)
BioLegend Inc. (U.S.)
https://www.24lifesciences.com/downloadsample/2932/interferon-gamma-ifn-elisa-kitmarket-market
https://www.24lifesciences.com
